[Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].

Autor:	Máspero J; Director Médico, Fundación CIDEA, Ciudad Autónoma de Buenos Aires. guiasdedermatitisatopica@protonmail.com., Angles MV; Servicio de Dermatología, Hospital Italiano, Ciudad Autónoma de Buenos Aires. maria.angles@hospitalitaliano.org.ar., Ardusso L; Servicio de Alergia e Inmunología, Hospital Provincial del Centenario, Rosario, Provincia de Santa Fe. ardussol2829@gmail.com., Brancciforte M; Centro Médico Dr. Ezequiel Chouela, Ciudad Autónoma de Buenos Aires. milibrancci@gmail.com., Castro C; Servicio de Dermatología, Hospital Universitario Austral (Universidad Austral), Pilar, Provincia de Buenos Aires. charliecastelman@yahoo.com., Cruz Iturrieta C; Dermatología, Lomas Medicina Especializada, Salta, Provincia de Salta. carmencruziturrieta@hotmail.com., Chouela E; Centro Médico Dr. Ezequiel Chouela, Ciudad Autónoma de Buenos Aires. echouela@gmail.com., De Gennaro MS; Vicedirectora Médica, Fundación CIDEA, Ciudad Autónoma de Buenos Aires. mdegennaro@fundacioncidea.org.ar., Fernández Bussy R; Servicio de Alergia e Inmunología, Hospital Provincial del Centenario, Rosario, Provincia de Santa Fe. ramonfbussy@gmail.com., Galimberti ML; Servicio de Dermatología, Hospital Italiano, Ciudad Autónoma de Buenos Aires. maria.galimberti@hospitalitaliano.org.ar., Galimberti RL; Servicio de Dermatología, Hospital Italiano, Ciudad Autónoma de Buenos Aires. ricardo.galimberti@gmail.com., Gattolin G; Investigación Farmacoclínica, Centro Respiratorio Infantil, Rosario, Provincia de Santa Fe. gabrielgattolin@gmail.com., Luna PC; Servicio de Dermatología, Hospital Alemán, Ciudad Autónoma de Buenos Aires. paulacarolinaluna@gmail.com., Magariños G; Psoriahue Medicina Interdisciplinaria, Ciudad Autónoma de Buenos Aires. gabriel.magarinos@gmail.com., Marini MG; Servicio de Dermatología, Sanatorio Güemes, Ciudad Autónoma de Buenos Aires. marianogmarini@gmail.com., Maskin M; Sección Dermatología, CEMIC, Ciudad Autónoma de Buenos Aires. matiasmaskin@yahoo.com.ar., Plafnik R; Servicio de Dermatología, Complejo Churruca-Visca, Ciudad Autónoma de Buenos Aires. rominaplafnik@gmail.com., Raimondo N; Servicio de Dermatología, Hospital Aeronáutico Central, Ciudad Autónoma de Buenos Aires. nraimondo_dermatologia@hotmail.com., Russo JP; Servicio de Dermatología, Hospital San Martin, La Plata, Provincia de Buenos Aires. juanpedrorusso@gmail.com., Sevinsky L; Consultorio Particular de Dermatología; Ciudad Autónoma de Buenos Aires. drsevinsky@hotmail.com., Stringa MF; Consultorio Particular de Dermatología; Ciudad Autónoma de Buenos Aires. matiasstringa@hotmail.com.
Jazyk:	Spanish; Castilian
Zdroj:	Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) [Rev Fac Cien Med Univ Nac Cordoba] 2020 Jun 09; Vol. 77 (2), pp. 94-99. Date of Electronic Publication: 2020 Jun 09.
DOI:	10.31053/1853.0605.v77.n2.27845
Abstrakt:	Introduction: Severe atopic dermatitis (AD) treatment is an unmet need, given the limited efficacy and safety of classical systemic treatments (CSTs). Dupilumab is a monoclonal antibody that blocks the signaling of the interleukins that mediate the inflammatory response involved in AD. Methods: the clinical response of a group of patients from Argentina with severe AD and insufficient response and/or toxicity to CSTs who were treated with dupilumab before commercial availability was analyzed. EASI, SCORAD, DLQI scales and analog visual scales of pruritus and sleep were evaluated, during a median follow-up of 189 days. In addition, the incidence of adverse events was analyzed. Results: 20 patients (13 male) were included; median age: 37.5 years; median AD evolution: 20 years; atopic comorbidity: 70%. 100% had received systemic corticosteroids (serious complications: 20%). Main reasons for discontinuation of CSTs were lack of efficacy and occurrence of adverse events. All scores were significantly and steadily reduced, with identifiable clinical response at the second month of treatment. At the end of the follow-up, only 3 patients required concomitant systemic immunosuppressive treatment. Dupilumab was well tolerated, with mild and controllable adverse events. Discussion: Dupilumab is the only biological agent with high efficacy demonstrated in clinical and observational studies. In this case series, its effectiveness was confirmed in difficult-to-treat patients with severe AD and inadequate response to CSTs. The safety profile was favorable and consistent. (Universidad Nacional de Córdoba)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu